Balazs Szamosfalvi, MD
Nephrology · Ann Arbor, MINPI 1639247174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,100 of the $2,881 with a category attached, or 72.9%. Fresenius USA Marketing, Inc. accounts for 72.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $2,100 and has fallen 66.9% since, to $694 in 2025.
Across 7 payments — averaging $411.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$2K
- Vantive US Healthcare LLC$537
- Nxstage Medical, Inc.$157
- Vifor Pharma, Inc.$87
Across 25 payments — averaging $10,234 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fresenius USA Marketing, Inc.$191K
- Baxter Healthcare$36K
- Fresenius Medical Care Renal Therapies Group, LLC.$18K
- Akebia Therapeutics Inc$11K
What the payments were for
- Speaking & faculty fees$2,10073%
- Travel & lodging$53719%
- Food & beverage$1575%
- Education$873%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 1 | $2,100 |
| Vantive US Healthcare LLC | 2 | $537 |
| Nxstage Medical, Inc. | 2 | $157 |
| Vifor Pharma, Inc. | 2 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Chronic$482
How this compares
$2,881 in reported general payments places this provider in the 70th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 11 | $187 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Ann Arbor
- Alexander YevzlinAnn Arbor$1.1M
- Laura MarianiAnn Arbor$150K
- Matthias KretzlerAnn Arbor$70K
- Lenar YessayanAnn Arbor$40K
- Bruce RobinsonAnn Arbor$38K
- Karthik RamaniAnn Arbor$27K
- Rajiv SaranAnn Arbor$23K
- Panduranga RaoAnn Arbor$20K
- Andrea OliverioAnn Arbor$15K
- Abhijit NaikAnn Arbor$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.